EMBC · CIK 0001872789
What Embecta Corp. told the SEC could break it.
Embecta's register is built on concentration at every link of its chain: pen needles alone were about $784 million, or 73%, of fiscal 2025 revenue; all production runs from just three plants (Ireland, the U.S. and China); and it buys certain raw materials and components from single suppliers who themselves sometimes depend on sole-sourced sub-suppliers. China recurs as a pressure point on two fronts — volume-based procurement and GPOs that threaten price erosion there, plus U.S.-China tariffs and export controls that raise its input costs. It also flags Red Sea shipping attacks as a source of supply-chain delays and route disruption.
6 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- three manufacturing sites (Ireland, U.S., China)medium
All production runs from just three manufacturing facilities, located in Ireland, the United States and China.
“Embecta has three manufacturing facilities located in Ireland, the United States, and China which occupy an aggregate of approximately 800,000 square feet of space.”
SEC filing →As of 2025 - Red Sea / Middle East shipping route disruptionlow
Attacks on shipping vessels in the Red Sea and Middle East hostilities have caused supply chain delays, price increases and shipping route disruptions.
“the hostilities in Israel and the Middle East, including attacks on shipping vessels in the Red Sea, could develop to have a more widespread economic and geopolitical affect in the Middle East and Europe”
SEC filing →As of 2025
Regulatory & policy
- China volume-based procurement and GPO price erosionmedium
In China, access via volume-based procurement and Group Purchasing Organizations threatens significant price erosion and cost containment.
“In China, the most notable threat continues to be access through volume-based procurement and Group Purchasing Organizations ("GPOs"), with potential significant price erosion and cost containment within the healthcare landscape.”
- U.S.-China tariffs and export controlsmedium
U.S. tariffs and export controls on Chinese imports and retaliatory tariffs raise import duties and input costs; Embecta exports raw materials and products into affected trade lanes.
“The United States has imposed tariffs and export controls on certain goods and products imported from China and certain other countries, which has resulted in retaliatory tariffs by China and other countries.”
Sole-source dependency
- single-source raw materials and componentshigh
Embecta buys certain raw materials and components from a single supplier, who in turn sometimes relies on their own single or sole-sourced sub-suppliers.
“for quality assurance, cost-effectiveness and other reasons, Embecta purchases certain raw materials and components from a single supplier, who in turn sometimes rely on their own single or sole sourced sub-suppliers for certain materials or components.”
SEC filing →As of 2025
Other disclosures
- single-product concentration (pen needles ~73% of revenue)medium
Pen needles alone accounted for ~$784M, or 73% of total net revenues in FY2025 — heavy dependence on one product line.
“for the fiscal year ended September 30, 2025, sales of pen needles accounted for approximately $784 million, or 73%, of total net revenues.”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.”
Cited →“for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.”
Cited →“for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch